US Financial Advisors’s Moderna MRNA Stock Holding History

US Financial Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,494	Closed	-$458K	–	110
2021 Q1	$458K	Buy	3,494 +51	+1%	+$7.39K	0.13%	84
2020 Q4	$360K	Buy	+3,443	New	+$348K	0.11%	83

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

US Financial Advisors's MRNA Position: Q2 2021 in Review

US Financial Advisors sold out of Moderna (MRNA) in Q2 2021, closing a stake of 3,494 shares — an estimated $458K sold.

US Financial Advisors first reported a position in MRNA in Q4 2020 and held it in 2 quarters. The position peaked at $458K in Q1 2021. 903 funds tracked by Wall St. Rank hold MRNA as of Q2 2021.

US Financial Advisors reported no remaining Moderna position as of Q2 2021 after selling out during the quarter.
US Financial Advisors sold 3,494 Moderna shares in Q2 2021, an estimated $458K.
US Financial Advisors first reported a position in Moderna in Q4 2020 and held it in 2 quarters.
US Financial Advisors's Moderna position peaked at $458K in Q1 2021.
903 funds tracked by Wall St. Rank held Moderna as of Q2 2021.

Based on US Financial Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.